2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies
2019 · Journal of Hematology & Oncology · 184 citations
https://doi.org/10.1186/s13045-019-0732-7
Y
Yingxi Xu
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
126
Papers
2.9K
Citations
29
h-index
49
i10-index
Yingxi Xu is an academic researcher from Tianjin University of Technology. The author has contributed to research in topics: CAR-T cell therapy research & Immune Cell Function and Interaction & Acute Myeloid Leukemia Research. The author has an h-index of 29, co-authored 108 publications.
ORCID: 0000-0002-0056-7440Papers by this author
worksEfficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
2020 · Journal of Hematology & Oncology · 107 citations
https://doi.org/10.1186/s13045-020-00953-8
Activating innate immune responses repolarizes hPSC-derived CAR macrophages to improve anti-tumor activity
2024 · Cell stem cell · 40 citations
https://doi.org/10.1016/j.stem.2024.04.012
Association of Overt and Subclinical Hyperthyroidism During Weeks 4–8 with Adverse Pregnancy Outcomes
2019 · Journal of Women s Health · 39 citations
https://doi.org/10.1089/jwh.2018.7180
T cell-based cancer immunotherapy: opportunities and challenges
2025 · Science Bulletin · 21 citations
https://doi.org/10.1016/j.scib.2025.03.054
Engineering cell-derived extracellular matrix for peripheral nerve regeneration
2024 · Materials Today Bio · 19 citations
https://doi.org/10.1016/j.mtbio.2024.101125
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat